Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVX836 Dose-Ranging Study for Influenza
NCT05060887Phase 2Completed
- Sponsor
- Osivax
- Start
- Nov 2021
- Primary completion
- Feb 2022
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of OVX836 in influenza, sponsored by Osivax. Started Nov 2021; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05060887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060887.